Market closed
Castle Biosciences/$CSTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Castle Biosciences
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, among others. The company's test portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology, and ophthalmology and a pharmacogenomics ("PGx") test to guide optimal drug treatment for patients diagnosed with depression, anxiety, and other mental health conditions.
Ticker
$CSTL
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
761
Website
CSTL Metrics
BasicAdvanced
$557M
31.52
$0.62
0.98
-
Price and volume
Market cap
$557M
Beta
0.98
52-week high
$33.33
52-week low
$16.97
Average daily volume
443K
Financial strength
Current ratio
7.292
Quick ratio
6.972
Long term debt to equity
5.353
Total debt to equity
5.801
Interest coverage (TTM)
15.03%
Management effectiveness
Return on assets (TTM)
1.10%
Return on equity (TTM)
4.31%
Valuation
Price to earnings (TTM)
31.516
Price to revenue (TTM)
1.634
Price to book
1.22
Price to tangible book (TTM)
1.59
Price to free cash flow (TTM)
14.853
Growth
Revenue change (TTM)
51.09%
Earnings per share change (TTM)
-128.92%
3-year revenue growth (CAGR)
52.25%
3-year earnings per share growth (CAGR)
-20.73%
What the Analysts think about CSTL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.
CSTL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CSTL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CSTL News
AllArticlesVideos
Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
Business Wire·2 weeks ago
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Castle Biosciences stock?
Castle Biosciences (CSTL) has a market cap of $557M as of March 13, 2025.
What is the P/E ratio for Castle Biosciences stock?
The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 31.52 as of March 13, 2025.
Does Castle Biosciences stock pay dividends?
No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of March 13, 2025.
When is the next Castle Biosciences dividend payment date?
Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Castle Biosciences?
Castle Biosciences (CSTL) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.